콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

Y0001517

Haloperidol for system suitability

European Pharmacopoeia (EP) Reference Standard

동의어(들):

Haloperidol, 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C21H23ClFNO2
CAS Number:
52-86-8
Molecular Weight:
375.86
MDL number:
MFCD00051423
UNSPSC 코드:
41116107
PubChem Substance ID:
329831468
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

haloperidol

제조업체/상표

EDQM

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3

InChI

1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

InChI key

LNEPOXFFQSENCJ-UHFFFAOYSA-N

유전자 정보

human ... HTR2A(3356)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Haloperidol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

관련 제품

제품 번호
설명
가격

H0100000

Haloperidol, European Pharmacopoeia (EP) Reference Standard

1303002

Haloperidol, United States Pharmacopeia (USP) Reference Standard

H0100100

Haloperidol decanoate, European Pharmacopoeia (EP) Reference Standard

Y0001518

Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard

1303013

Haloperidol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1303057

Haloperidol decanoate, United States Pharmacopeia (USP) Reference Standard

1303024

Haloperidol Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR1724

Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material

BP407

Haloperidol, British Pharmacopoeia (BP) Reference Standard

PHR8951

Haloperidol Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8714

Haloperidol Related Compound B, certified reference material, pharmaceutical secondary standard

픽토그램

Skull and crossbonesHealth hazard
GHS06,GHS08

신호어

Danger

유해 및 위험 성명서

H301,H315,H317,H319,H335,H361

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

표적 기관

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

Choose from one of the most recent versions:

시험 성적서(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Gerard W K Hugenholtz et al.
The Journal of clinical psychiatry, 67(6), 897-903 (2006-07-20)
To determine the doses of haloperidol as a comparator drug in randomized controlled trials (RCTs) with atypical antipsychotics in patients with schizophrenia and to compare these doses with the officially recommended doses for haloperidol in the United States and the
Mark C Fok et al.
International journal of geriatric psychiatry, 30(4), 333-344 (2015-02-03)
To summarize the effect of antipsychotics for preventing postoperative delirium. We conducted a literature search using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and clinicaltrials.gov. We included randomized controlled trials of adults undergoing surgery
Paul Perkins et al.
The Cochrane database of systematic reviews, (2)(2), CD006271-CD006271 (2009-04-17)
Nausea and vomiting are common symptoms of patients with terminal, incurable illnesses and can be distressing. The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of
Marianne Klemp et al.
Journal of clinical psychopharmacology, 31(6), 698-704 (2011-10-25)
The objective of the study was to examine the efficacy and the degree of adverse effects connected with atypical neuroleptic drugs and haloperidol by using a previously described Bayesian statistical method that includes both direct and indirect comparisons simultaneously. The
Lorna Donnelly et al.
The Cochrane database of systematic reviews, 8(8), CD001951-CD001951 (2013-08-29)
Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged. To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia. We searched the Cochrane Schizophrenia Group
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.